About this trial
The goal of this clinical trial is to learn if using an intervention website (Mosaic) improves selected patient-reported outcomes in adult blood cancer patients undergoing allogeneic or autologous stem cell transplant, compared to using an educational website (control group). Patients will be recruited prior to their scheduled transplant, then randomized to use one of these two study websites throughout the study. They will complete five assessments during the study: one before transplant (baseline) and four after transplant (2, 4, 6, and 8 month follow-ups).
The main questions this trial aims to answer are:
1. Compared to patients using the control group website, do patients using the intervention website report greater improvements in general psychological distress, cancer treatment-related distress, physical symptoms, and health-related quality of life? 2. Are these benefits at least partially explained by improvements in perceived preparedness, self-efficacy, and approach coping and/or reductions in avoidant coping and perceived stress? 3. Do some patients benefit more from using the intervention website than others? Specifically, we will examine whether patients' primary language (English/Spanish) and their initial psychological distress are related to the benefit they get from using the intervention website. We will also explore effects of sex, race, ethnicity, and transplant type.
Eligibility criteria
Qualifiers
Diagnosed with a hematologic cancer according to medical records
Scheduled for or preparing for scheduling of an allogeneic or autologous stem cell transplant at one of our study sites
Aged 18 or older (no upper limit)
English or Spanish Proficient
Disqualifiers
Currently participating in a behavioral intervention targeting distress, health-related quality of life, or symptoms
Undergoing the first in a planned tandem stem cell transplant
Unable to provide meaningful consent (severe cognitive impairment or language difficulties)
Trial design
Treatments tested in this trial
- Intervention website
- Enhanced Usual Care (Control) Website
Treatment groups
Sponsors and collaborators
Northwestern University
Lead sponsor
Georgetown University
Collaborator
Hackensack Meridian Health
Collaborator
National Cancer Institute (NCI)
Collaborator